AYTU BIOPHARMA, INC. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2024 (Q2 of Fiscal Year 2025). Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing prescription therapeutics, primarily for pediatric conditions. Following the divestiture of its Consumer Health business in July 2024, the Company now operates as a single segment comprising two portfolios: the ADHD Portfolio (Adzenys, Cotempla) and the Pediatric Portfolio (Karbinal, Poly-Vi-Flor, Tri-Vi-Flor). The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 | Balance Sheet (Dec 31, 2024) |
|---|---|---|---|
| Net Revenue | $16,221 | $32,795 | - |
| Gross Profit | $10,786 | $22,771 | - |
| Gross Margin | 66.5% | 69.4% | - |
| Net Income (Loss) | $788 | $2,262 | - |
| Operating Cash Flow | - | $1,715 | - |
| Cash and Equivalents | - | - | $20,398 |
| Total Debt (Current + Non-Current) | - | - | $15,852 |
| Derivative Warrant Liabilities | - | - | $6,386 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 13% ($2.5M) for the quarter and 10% ($3.8M) for the six months compared to the prior year. The decline was driven by a return to normalized demand in the ADHD Portfolio following competitor shortages and payer coverage changes in the Pediatric Portfolio. This was partially offset by a $3.3M revenue increase in Q1 2025 due to successful vendor negotiations reducing variable consideration accruals.
- Profitability: The Company reported a net income of $0.8M for the quarter and $2.3M for the six months, a significant improvement from the net losses of $0.2M and $8.3M in the prior year periods. This turnaround was primarily driven by a $3.0M gain (quarter) and $5.9M gain (six months) from the revaluation of derivative warrant liabilities due to a decrease in stock price.
- Operating Expenses: Operating expenses increased by $1.0M for the quarter due to $1.3M in restructuring costs related to the closure of the Grand Prairie, Texas manufacturing site. General and administrative expenses decreased by 7% due to cost reduction efforts.
- Debt Restructuring: In June 2024, the Company refinanced its debt, repaying a $15.0M Avenue Capital loan with proceeds from a new $13.0M Eclipse Term Loan and a $14.5M revolving credit facility.
Guidance, Outlook, and Risks
- Outlook: Management is focusing on accelerating commercial growth and achieving positive operating cash flows. Active clinical development has been indefinitely suspended. The Company has secured international distribution agreements for its ADHD products in Israel/Palestine (Medomie) and Canada (Lupin), with regulatory approvals expected in 18-24 months.
- Liquidity: As of December 31, 2024, the Company held $20.4M in cash and cash equivalents. It has $7.9M of unused capacity on its revolving credit facility and a $100M shelf registration effective for future capital raises.
- Legal Risks:
- Granules PIV: The Company filed a patent infringement lawsuit against Granules Pharmaceuticals regarding a generic version of Adzenys. A trial is scheduled for December 2026.
- Witmer Litigation: A stockholder derivative suit was settled in January 2025 for corporate governance modifications and attorney fees.
- Unusual Items: The financial results include significant non-cash gains from derivative warrant liabilities and restructuring charges. The Company also recorded a $3.8M Employee Retention Credit (ERC) liability which is recognized as income only when realizable.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the sensitivity of net income to stock price fluctuations, as the $5.9M gain in the six-month period was entirely non-cash and driven by warrant revaluation.
- Debt Covenants: Review the financial covenants under the new Eclipse Agreement (SOFR + 7.0% for term loan) and ensure compliance, particularly regarding the borrowing base for the revolving facility.
- Restructuring Completion: Confirm that the $2.1M in restructuring costs incurred to date represent the full scope of exit costs for the Grand Prairie facility closure.
- Patent Litigation Status: Monitor the Granules Pharmaceuticals litigation, as a loss could accelerate generic competition for the core Adzenys product.
- Discontinued Operations: Note that the Consumer Health business is reported as discontinued; verify that no contingent consideration from the divestiture has been recognized yet.